VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 457 USD | +1.36% |
|
+2.64% | +12.30% |
Financials (USD)
| Sales 2024 * | 10.75B | Sales 2025 * | 11.67B | Capitalization | 118B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.99B | Net income 2025 * | 4.46B | EV / Sales 2024 * | 9.67 x |
| Net cash position 2024 * | 13.97B | Net cash position 2025 * | 18.59B | EV / Sales 2025 * | 8.51 x |
| P/E ratio 2024 * |
30
x | P/E ratio 2025 * |
26.7
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | +1.36% | ||
| 1 week | +2.64% | ||
| Current month | +16.33% | ||
| 1 month | +14.96% | ||
| 3 months | +5.41% | ||
| 6 months | +29.43% | ||
| Current year | +12.30% |
1 week
437.46
457.66
1 month
391.70457.66
Current year
391.01457.66
1 year
320.01457.66
3 years
176.36457.66
5 years
165.23457.66
10 years
63.68457.66
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 56 | 19-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 457 | +1.36% | 1,050,952 |
| 24-05-23 | 450.8 | +0.73% | 1,554,896 |
| 24-05-22 | 447.5 | +1.25% | 1,084,642 |
| 24-05-21 | 442 | -0.87% | 1,106,759 |
| 24-05-20 | 445.9 | +0.15% | 742,237 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-06-04
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B | |
| -31.18% | 7.55B |
- Stock Market
- Equities
- VRTX Stock
